DrugMax, Inc. today reported that preliminary April and May 2006 sales were $18.4 million and $19.0 million respectively, representing an 8.2% and 11.8% increase over April and May 2005 sales of $17.0 million and $17.0 million, respectively. Combined April and May sales totaled $37.4 million, representing an increase of 10% over the combined $34.0 million sales reported in April and May last year and an increase of 11.6% over the combined $33.5 million sales reported in January and February in the first quarter of 2006. PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/06-14-2006/0004380552&EDATE=)
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
Cerapedics Earns Premarket Approval for Bone Graft
The premarket approval allows the labeling to state that clinical data showed statistical superiority over autologous bone graft was maintained in its second-year follow-up.
Reblozyl Earns FDA’s First Approval for Rare Blood Disorder
Reblozyl was previously granted both fast track and orphan drug designations.
